This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dörk, T. Articles by Karstens, J. H. Search for Related Content PubMed PubMed Citation Articles by Dörk, T. Articles by Karstens, J. H.

Spectrum of ATM Gene Mutations in a Hospital-based Series of Unselected Breast Cancer Patients¹

Department of Biochemistry and Tumour Biology, Clinic of Obstetrics and Gynecology [T. D., R. B., K. K., A. H., P. Y., D. S.], Department of Radiation Oncology [R. B., M. B., D. R., M. N., J. H. K.], Institute of Human Genetics [M. N., B. S., M. S.], and Department of Haematology and Oncology [D. S.], Medical School Hannover, D-30659 Hannover; and Center for Child Neurology, Hospital Gerresheim, D-40225 Düsseldorf [S. W.], Germany

Blood relatives of patients with the inherited disease ataxia telangiectasia (A-T) have an increased susceptibility for breast cancer. We therefore looked for sequence alterations of the ATM gene in a large hospital-based series of unselected breast cancer patients. The whole ATM coding sequence was analyzed in genomic DNA samples from a core group of 192 consecutive breast cancer cases to define the spectrum of ATM gene mutations. Common sequence alterations were then screened in the whole series of 1000 breast cancer patients and in 500 random individuals. In the core group, 21 distinct sequence alterations were identified throughout the ATM coding region, and 1 common splicing mutation was uncovered in intron 10. Almost half of the breast cancer patients (46%) were heterozygotes for 1 of 16 different amino acid substitutions, and three patients (1.6%) carried a truncating mutation. These data indicate that 1 in 50 German breast cancer patients is heterozygous for an A-T-causing mutation. In our extended series, the most common A-T mutation 1066-6TG was disclosed in 7 of 1000 (0.7%) breast cancer patients. Transcript analyses indicated that the loss of exon 11 in the ATM mRNA was the pathogenic consequence of this splicing mutation, which produced a <10% of full-length ATM mRNA and ATM protein in a homozygous A-T patient. We also found an excess of rare missense substitutions in the breast cancer cohort compared with random individuals (7.9% versus 5.3% of alleles; odds ratio = 1.6; P < 0.01). One missense substitution, S707P in exon 15, was two times more frequent in breast cancer patients (odds ratio = 2.4; 95% confidence interval, 1.0–5.8) and five times more frequent in patients with bilateral disease than in random individuals (P < 0.001). We conclude that a large variety of distinct ATM mutations and variants exist among breast cancer patients, some of which can contribute to the etiology and progression of the malignancy. Screening for frequent A-T mutations such as the 1066-6G splice site substitution can be effective to prospectively identify A-T heterozygotes in an unselected cancer patient population.

This article has been cited by other articles:

				S. A. Nahas, A. W. Butch, L. Du, and R. A. Gatti Rapid Flow Cytometry-Based Structural Maintenance of Chromosomes 1 (SMC1) Phosphorylation Assay for Identification of Ataxia-Telangiectasia Homozygotes and Heterozygotes Clin. Chem., March 1, 2009; 55(3): 463 - 472. [Abstract] [Full Text] [PDF]

				M. Swift and J. L. Lukin Breast Cancer Incidence and the Effect of Cigarette Smoking in Heterozygous Carriers of Mutations in the Ataxia-Telangiectasia Gene Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3188 - 3192. [Abstract] [Full Text] [PDF]

				I. A. Barbazetto, M. Room, N. A. Yannuzzi, G. R. Barile, J. E. Merriam, A. M. C. Bardal, K. B. Freund, L. A. Yannuzzi, and R. Allikmets ATM Gene Variants in Patients with Idiopathic Perifoveal Telangiectasia Invest. Ophthalmol. Vis. Sci., September 1, 2008; 49(9): 3806 - 3811. [Abstract] [Full Text] [PDF]

				S. L. Dombernowsky, M. Weischer, K. H. Allin, S. E. Bojesen, A. Tybjjrg-Hansen, and B. G. Nordestgaard Risk of Cancer by ATM Missense Mutations in the General Population J. Clin. Oncol., June 20, 2008; 26(18): 3057 - 3062. [Abstract] [Full Text] [PDF]

				E. Seemanova, P. Jarolim, P. Seeman, R. Varon, M. Digweed, M. Swift, and K. Sperling Cancer Risk of Heterozygotes With the NBN Founder Mutation J Natl Cancer Inst, December 19, 2007; 99(24): 1875 - 1880. [Abstract] [Full Text] [PDF]

				M. K. Schmidt, S. Reincke, A. Broeks, L. M. Braaf, F. B.L. Hogervorst, R. A.E.M. Tollenaar, N. Johnson, O. Fletcher, J. Peto, J. Tommiska, et al. Do MDM2 SNP309 and TP53 R72P Interact in Breast Cancer Susceptibility? A Large Pooled Series from the Breast Cancer Association Consortium Cancer Res., October 1, 2007; 67(19): 9584 - 9590. [Abstract] [Full Text] [PDF]

				K. Pylkas, J. Tommiska, K. Syrjakoski, J. Kere, M. Gatei, N. Waddell, M. Allinen, S.-M. Karppinen, K. Rapakko, H. Kaariainen, et al. Evaluation of the role of Finnish ataxia-telangiectasia mutations in hereditary predisposition to breast cancer Carcinogenesis, May 1, 2007; 28(5): 1040 - 1045. [Abstract] [Full Text] [PDF]

				J. H. Kim, H. Kim, K. Y. Lee, K.-H. Choe, J.-S. Ryu, H. I. Yoon, S. W. Sung, K.-Y. Yoo, and Y.-C. Hong Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk Hum. Mol. Genet., April 1, 2006; 15(7): 1181 - 1186. [Abstract] [Full Text] [PDF]

				D. Thompson, S. Duedal, J. Kirner, L. McGuffog, J. Last, A. Reiman, P. Byrd, M. Taylor, and D. F. Easton Cancer Risks and Mortality in Heterozygous ATM Mutation Carriers J Natl Cancer Inst, June 1, 2005; 97(11): 813 - 822. [Abstract] [Full Text] [PDF]

				K.-M. Lee, J.-Y. Choi, S. K. Park, H.-W. Chung, B. Ahn, K.-Y. Yoo, W. Han, D.-Y. Noh, S.-H. Ahn, H. Kim, et al. Genetic Polymorphisms of Ataxia Telangiectasia Mutated and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 821 - 825. [Abstract] [Full Text] [PDF]

				A. W. Butch, H. H. Chun, S. A. Nahas, and R. A. Gatti Immunoassay to Measure Ataxia-Telangiectasia Mutated Protein in Cellular Lysates Clin. Chem., December 1, 2004; 50(12): 2302 - 2308. [Abstract] [Full Text] [PDF]

				M. S. Lim and K. S.J. Elenitoba-Johnson The Molecular Pathology of Primary Immunodeficiencies J. Mol. Diagn., May 1, 2004; 6(2): 59 - 83. [Full Text] [PDF]

				C. I. Szabo, M. Schutte, A. Broeks, J. J. Houwing-Duistermaat, Y. R. Thorstenson, F. Durocher, R. A. Oldenburg, M. Wasielewski, F. Odefrey, D. Thompson, et al. Are ATM Mutations 7271T->G and IVS10-6T->G Really High-Risk Breast Cancer-Susceptibility Alleles? Cancer Res., February 1, 2004; 64(3): 840 - 843. [Abstract] [Full Text] [PDF]

				M. Takagi, R. Tsuchida, K. Oguchi, T. Shigeta, S. Nakada, K. Shimizu, M. Ohki, D. Delia, L. Chessa, Y. Taya, et al. Identification and characterization of polymorphic variations of the ataxia telangiectasia mutated (ATM) gene in childhood Hodgkin disease Blood, January 1, 2004; 103(1): 283 - 290. [Abstract] [Full Text] [PDF]

				S. Angele, P. Romestaing, N. Moullan, M. Vuillaume, B. Chapot, M. Friesen, W. Jongmans, D. G. Cox, P. Pisani, J.-P. Gerard, et al. ATMHaplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity Cancer Res., December 15, 2003; 63(24): 8717 - 8725. [Abstract] [Full Text] [PDF]

				P. Bretsky, C. A. Haiman, S. Gilad, J. Yahalom, A. Grossman, S. Paglin, D. Van Den Berg, L. N. Kolonel, R. Skaliter, and B. E. Henderson The Relationship between Twenty Missense ATM Variants and Breast Cancer Risk: The Multiethnic Cohort Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 733 - 738. [Abstract] [Full Text] [PDF]

				Y. R. Thorstenson, A. Roxas, R. Kroiss, M. A. Jenkins, K. M. Yu, T. Bachrich, D. Muhr, T. L. Wayne, G. Chu, R. W. Davis, et al. Contributions of ATM Mutations to Familial Breast and Ovarian Cancer Cancer Res., June 15, 2003; 63(12): 3325 - 3333. [Abstract] [Full Text] [PDF]

				K. Offit, S. Gilad, S. Paglin, P. Kolachana, L. C. Roisman, K. Nafa, V. Yeugelewitz, M. Gonzales, M. Robson, D. McDermott, et al. Rare Variants of ATM and Risk for Hodgkin's Disease and Radiation-associated Breast Cancers Clin. Cancer Res., December 1, 2002; 8(12): 3813 - 3819. [Abstract] [Full Text] [PDF]

				P Maillet, H Bonnefoi, G Vaudan-Vutskits, B Pajk, T Cufer, W D Foulkes, P O Chappuis, and A-P Sappino Constitutional alterations of the ATM gene in early onset sporadic breast cancer J. Med. Genet., October 1, 2002; 39(10): 751 - 753. [Full Text] [PDF]

				K. Gronbak, J. Worm, E. Ralfkiaer, V. Ahrenkiel, P. Hokland, and P. Guldberg ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma Blood, July 30, 2002; 100(4): 1430 - 1437. [Abstract] [Full Text] [PDF]

				H. Lei, D. Pospisilova, A. Lindblom, and I. Vorechovsky Re: Dominant Negative ATM Mutations in Breast Cancer Families J Natl Cancer Inst, June 19, 2002; 94(12): 951 - 952. [Full Text] [PDF]

				G. Chenevix-Trench, A. B. Spurdle, M. Gatei, H. Kelly, A. Marsh, X. Chen, K. Donn, M. Cummings, D. Nyholt, M. A. Jenkins, et al. Dominant Negative ATM Mutations in Breast Cancer Families J Natl Cancer Inst, February 6, 2002; 94(3): 205 - 215. [Abstract] [Full Text] [PDF]

				S. P. Scott, R. Bendix, P. Chen, R. Clark, T. Dork, and M. F. Lavin Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer PNAS, January 22, 2002; 99(2): 925 - 930. [Abstract] [Full Text] [PDF]